Compass Therapeutics Inc
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
CMPX$0.84+0.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
(In thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(49,375) | $(42,494) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 589 | 699 |
| Share-based compensation | 8,560 | 6,120 |
| Amortization of premium and discount on marketable securities | (1,651) | (3,226) |
| ROU asset amortization | 1,164 | 1,191 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (4,857) | 6,762 |
| Accounts payable | (1,841) | 708 |
| Accrued expenses | 3,773 | (9,176) |
| Operating lease liability | (1,217) | (1,202) |
| Net cash used in operating activities | (44,855) | (40,618) |
| Cash flows from investing activities: | ||
| Purchases of marketable securities | (88,158) | (155,418) |
| Proceeds from sale or maturities of marketable securities | 134,974 | 182,413 |
| Purchases of property and equipment | (44) | (30) |
| Net cash provided by in investing activities | 46,772 | 26,965 |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock | 18,113 | 3,126 |
| Issuance costs from issuance of common stock | (543) | (94) |
| Proceeds from exercise of stock options | — | 62 |
| Taxes related to the vesting of RSUs | (232) | (159) |
| Net cash provided by financing activities | 17,338 | 2,935 |
| Net change in cash and cash equivalents | 19,255 | (10,718) |
| Cash and cash equivalents at beginning of year | 24,228 | 34,946 |
| Cash and cash equivalents at end of year | $43,483 | $24,228 |
| Supplemental disclosure of cash flow information | ||
| Unrealized gain on marketable securities | $(173) | $(339) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.